Compare MBWM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBWM | IOVA |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 763.4M | 968.6M |
| IPO Year | 1997 | N/A |
| Metric | MBWM | IOVA |
|---|---|---|
| Price | $49.26 | $2.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $52.88 | $10.36 |
| AVG Volume (30 Days) | 63.6K | ★ 9.8M |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ 6.26 | N/A |
| EPS | ★ 5.27 | N/A |
| Revenue | $233,714,000.00 | ★ $250,425,000.00 |
| Revenue This Year | $10.44 | $60.94 |
| Revenue Next Year | $11.11 | $60.85 |
| P/E Ratio | $9.35 | ★ N/A |
| Revenue Growth | 5.19 | ★ 175.62 |
| 52 Week Low | $37.76 | $1.64 |
| 52 Week High | $51.89 | $8.56 |
| Indicator | MBWM | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 46.56 |
| Support Level | $46.94 | $2.18 |
| Resistance Level | $47.77 | $2.32 |
| Average True Range (ATR) | 0.99 | 0.12 |
| MACD | 0.35 | -0.01 |
| Stochastic Oscillator | 93.08 | 18.11 |
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.